YMAB

Y-mAbs TherapeuticsNasdaqGS:YMAB Stock Report

Market Cap

US$1.3b

7D

-11.8%

1Y

-19.4%

Updated

22 Sep, 2021

Data

Company Financials +
YMAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

YMAB Overview

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Y-mAbs Therapeutics
Historical stock prices
Current Share PriceUS$29.87
52 Week HighUS$24.78
52 Week LowUS$55.22
Beta1.17
1 Month Change3.00%
3 Month Change-13.30%
1 Year Change-19.36%
3 Year Change20.83%
5 Year Changen/a
Change since IPO24.46%

Recent News & Updates

Aug 11
Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New Forecasts

Brokers Are Upgrading Their Views On Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) With These New Forecasts

Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

YMABUS BiotechsUS Market
7D-11.8%-0.9%-1.7%
1Y-19.4%28.4%36.2%

Return vs Industry: YMAB underperformed the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: YMAB underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is YMAB's price volatile compared to industry and market?
YMAB volatility
YMAB Beta1.17
Industry Beta1.03
Market Beta1

Stable Share Price: YMAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: YMAB's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015125Claus Møller San Pedrohttps://www.ymabs.com

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Y-mAbs Therapeutics Fundamentals Summary

How do Y-mAbs Therapeutics's earnings and revenue compare to its market cap?
YMAB fundamental statistics
Market CapUS$1.30b
Earnings (TTM)-US$42.29m
Revenue (TTM)US$37.08m

35.1x

P/S Ratio

-30.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YMAB income statement (TTM)
RevenueUS$37.08m
Cost of RevenueUS$2.71m
Gross ProfitUS$34.38m
ExpensesUS$76.67m
Earnings-US$42.29m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.02
Gross Margin92.70%
Net Profit Margin-114.04%
Debt/Equity Ratio0%

How did YMAB perform over the long term?

See historical performance and comparison

Valuation

Is Y-mAbs Therapeutics undervalued compared to its fair value and its price relative to the market?

5.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate YMAB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate YMAB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: YMAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: YMAB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate YMAB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: YMAB is overvalued based on its PB Ratio (5.6x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Y-mAbs Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

70.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: YMAB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: YMAB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: YMAB's is expected to become profitable in the next 3 years.

Revenue vs Market: YMAB's revenue (48.5% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: YMAB's revenue (48.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: YMAB is forecast to be unprofitable in 3 years.


Past Performance

How has Y-mAbs Therapeutics performed over the past 5 years?

-32.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: YMAB is currently unprofitable.

Growing Profit Margin: YMAB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YMAB is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.

Accelerating Growth: Unable to compare YMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: YMAB has a negative Return on Equity (-18.05%), as it is currently unprofitable.


Financial Health

How is Y-mAbs Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: YMAB's short term assets ($249.4M) exceed its short term liabilities ($21.0M).

Long Term Liabilities: YMAB's short term assets ($249.4M) exceed its long term liabilities ($4.2M).


Debt to Equity History and Analysis

Debt Level: YMAB is debt free.

Reducing Debt: YMAB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YMAB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: YMAB has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 41.2% each year.


Dividend

What is Y-mAbs Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate YMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate YMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YMAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YMAB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of YMAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Claus Møller San Pedro (59 yo)

6.25yrs

Tenure

US$8,192,780

Compensation

Dr. Claus Juan Møller San Pedro, M.D., Ph.D. has been Chief Executive Officer of Y-mAbs Therapeutics, Inc. since June 2015 and serves as its Director. Dr. Møller was the founder of Azanta A/S, or Azanta, a...


CEO Compensation Analysis

Compensation vs Market: Claus's total compensation ($USD8.19M) is above average for companies of similar size in the US market ($USD3.70M).

Compensation vs Earnings: Claus's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: YMAB's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: YMAB's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: YMAB insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.


Top Shareholders

Company Information

Y-mAbs Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Y-mAbs Therapeutics, Inc.
  • Ticker: YMAB
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.302b
  • Shares outstanding: 43.58m
  • Website: https://www.ymabs.com

Number of Employees


Location

  • Y-mAbs Therapeutics, Inc.
  • 230 Park Avenue
  • Suite 3350
  • New York
  • New York
  • 10169
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:45
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.